NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$189.25 -0.17 (-0.09 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$189.25
Today's Range$187.92 - $189.75
52-Week Range$107.64 - $196.56
Volume277,322 shs
Average Volume413,601 shs
Market Capitalization$4.03 billion
P/E Ratio73.64
Dividend YieldN/A
Beta0.92

About Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500

Debt

Debt-to-Equity Ratio0.03
Current Ratio1.41
Quick Ratio1.37

Price-To-Earnings

Trailing P/E Ratio73.64
Forward P/E Ratio43.71
P/E Growth1.75

Sales & Book Value

Annual Sales$141.10 million
Price / Sales28.57
Cash Flow$3.7669 per share
Price / Cash50.24
Book Value$22.58 per share
Price / Book8.38

Profitability

EPS (Most Recent Fiscal Year)$2.57
Net Income$12.55 million
Net Margins31.40%
Return on Equity19.10%
Return on Assets11.69%

Miscellaneous

Employees39
Outstanding Shares21,300,000

Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals (NASDAQ:LGND) announced its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $1.55 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.29 by $0.26. The biotechnology company had revenue of $56.16 million for the quarter, compared to the consensus estimate of $43.02 million. Ligand Pharmaceuticals had a net margin of 31.40% and a return on equity of 19.10%. The company's revenue was up 91.9% on a year-over-year basis. During the same period last year, the firm earned $0.57 EPS. View Ligand Pharmaceuticals' Earnings History.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Ligand Pharmaceuticals.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $4.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.56. The company issued revenue guidance of $184 million, compared to the consensus revenue estimate of $186.50 million.

What price target have analysts set for LGND?

5 brokerages have issued 1-year price objectives for Ligand Pharmaceuticals' stock. Their predictions range from $105.00 to $200.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $159.00 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals.

What are Wall Street analysts saying about Ligand Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Ligand’s earnings and revenues beat estimates in fourth-quarter 2017. The company’s captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could bring in future licensing opportunities. Additionally, the company’s entry into the Medical Devices Segment with the buyout of multiple programs owned by CorMatrix is encouraging. Shares of Ligand have outperformed the broader industry in the past year. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to these two products could leave a substantial impact. Moreover, Ligand’s dependence on a single supplier to obtain Captisol is concerning." (2/28/2018)
  • 2. HC Wainwright analysts commented, "Kyprolis Beats; Recent and Anticipated Label Expansions Represent Revenue Inflection Points Kyprolis quickly approaching blockbuster status. Yesterday, partner Amgen (AMGN; not rated) announced 4Q17 and 2017 Kyprolis revenue of $227M and $835M, respectively, compared with our estimates of $220M (consensus $225M) and $828M. As Kyprolis approaches blockbuster status, considering certain factors we think should be able to easily push it over the edge, and they include: 1) recent FDA approval of sNDA based on ENDEAVOR overall survival data; 2) recent CHMP positive opinion to include updated overall survival from ENDEAVOR on label this year in the E.U.; and 3) recent submission of sNDA to FDA and a variation to the marketing authorization to the EMA, both based on the overall survival benefit from the ASPIRE study (actions expected this year). Upcoming milestones and key programs underway: 2018 initial visibility from recent launch of Baxdela for serious skin infections." (2/2/2018)

Who are some of Ligand Pharmaceuticals' key competitors?

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the folowing people:
  • Mr. John L. Higgins, CEO & Exec. Director (Age 48)
  • Mr. Matthew W. Foehr, Pres & COO (Age 45)
  • Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 43)
  • Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)
  • Ms. Audrey Warfield-Graham, VP of HR

Has Ligand Pharmaceuticals been receiving favorable news coverage?

News coverage about LGND stock has trended positive this week, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a coverage optimism score of 0.30 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 44.00 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.22%), Summit Trail Advisors LLC (9.15%), Knott David M (2.61%), Victory Capital Management Inc. (2.41%), Cardinal Capital Management LLC CT (2.06%) and Eagle Asset Management Inc. (2.06%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

Which major investors are selling Ligand Pharmaceuticals stock?

LGND stock was sold by a variety of institutional investors in the last quarter, including Cardinal Capital Management LLC CT, Knott David M, Oak Ridge Investments LLC, Russell Investments Group Ltd., Elk Creek Partners LLC, Eaton Vance Management, Next Century Growth Investors LLC and Mesirow Financial Investment Management Equity Management. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.

Which major investors are buying Ligand Pharmaceuticals stock?

LGND stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, UBS Group AG, Matarin Capital Management LLC, Penserra Capital Management LLC, OppenheimerFunds Inc., King Luther Capital Management Corp, BlackRock Inc. and Chicago Equity Partners LLC. View Insider Buying and Selling for Ligand Pharmaceuticals.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $189.25.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $4.03 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]


MarketBeat Community Rating for Ligand Pharmaceuticals (LGND)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  341 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  539
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Ligand Pharmaceuticals in the last 12 months. Their average twelve-month price target is $159.00, suggesting that the stock has a possible downside of 15.98%. The high price target for LGND is $200.00 and the low price target for LGND is $105.00. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.602.60
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $159.00$159.00$152.00$145.80
Price Target Upside: 15.98% downside4.14% downside2.78% downside12.13% upside

Ligand Pharmaceuticals (NASDAQ:LGND) Consensus Price Target History

Price Target History for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ:LGND) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018HC WainwrightReiterated RatingBuy$182.00HighView Rating Details
3/7/2018Craig HallumReiterated RatingBuy$190.00 ➝ $200.00MediumView Rating Details
2/26/2018Roth CapitalBoost Price TargetBuy$158.00 ➝ $171.00LowView Rating Details
11/20/2017Deutsche BankDowngradeHold ➝ Sell$105.00N/AView Rating Details
8/9/2017StephensReiterated RatingOverweight$125.00 ➝ $137.00LowView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 ➝ $125.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Ligand Pharmaceuticals (NASDAQ:LGND) Earnings History and Estimates Chart

Earnings by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ:LGND) Earnings Estimates

Current Year EPS Consensus Estimate: $4.33 EPS
Next Year EPS Consensus Estimate: $5.29 EPS

Ligand Pharmaceuticals (NASDAQ LGND) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/8/2018Q1 2018$1.29$1.55$43.02 million$56.16 millionViewN/AView Earnings Details
2/21/2018Q4 2017$1.19$1.31$49.39 million$50.50 millionViewListenView Earnings Details
11/9/2017Q3 2017$0.37$0.69$31.04 million$33.38 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.25$0.67$24.40 million$28.00 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
8/8/2012Q2 2012($0.03)($0.20)ViewN/AView Earnings Details
5/2/2012Q1 2012$0.02($0.02)ViewN/AView Earnings Details
2/7/2012Q4 2011$0.02$0.24ViewN/AView Earnings Details
11/8/2011Q3 2011($0.20)ViewN/AView Earnings Details
8/8/2011Q2 2011$0.01($0.05)ViewN/AView Earnings Details
5/10/2011Q1 2011$0.04($0.06)ViewN/AView Earnings Details
2/15/2011Q4 2010$0.02$0.24ViewN/AView Earnings Details
11/9/2010Q3 2010($3.62)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.06($0.01)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.18)($0.15)ViewN/AView Earnings Details
2/9/2010Q4 2009$0.07ViewN/AView Earnings Details
11/5/2009Q3 2009($0.30)($0.18)ViewN/AView Earnings Details
8/3/2009Q2 2009($0.42)($0.22)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.24)($0.29)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.36)($0.11)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.42)($0.31)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.12)($0.61)ViewN/AView Earnings Details
2/20/2008Q4 2007$0.24($0.34)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ligand Pharmaceuticals (NASDAQ:LGND) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Insider Trading History for Ligand Pharmaceuticals (NASDAQ:LGND)
Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018John L HigginsCEOSell12,405$179.97$2,232,527.85119,824View SEC Filing  
5/10/2018Matthew W FoehrInsiderSell8,881$167.63$1,488,722.03110,082View SEC Filing  
4/2/2018John W KozarichDirectorSell2,500$160.43$401,075.00View SEC Filing  
3/12/2018Stephen L SabbaDirectorSell622$180.73$112,414.0626,363View SEC Filing  
3/9/2018Jason AryehDirectorSell7,500$175.73$1,317,975.0058,625View SEC Filing  
3/5/2018John L LamattinaDirectorSell3,335$160.90$536,601.5024,291View SEC Filing  
2/27/2018Todd C DavisDirectorSell17,170$152.37$2,616,192.9065,898View SEC Filing  
2/23/2018Jason AryehDirectorSell3,417$155.00$529,635.0058,625View SEC Filing  
2/23/2018Matthew W FoehrCOOSell5,444$152.98$832,823.1295,835View SEC Filing  
2/15/2018John L HigginsCEOSell9,000$157.03$1,413,270.00102,700View SEC Filing  
1/24/2018John L HigginsCEOSell22,500$165.00$3,712,500.00111,700View SEC Filing  
1/19/2018John L HigginsCEOSell28,099$153.70$4,318,816.30162,299View SEC Filing  
1/10/2018John W KozarichDirectorSell2,500$145.00$362,500.0033,149View SEC Filing  
12/20/2017Stephen L SabbaDirectorSell925$137.25$126,956.2526,985View SEC Filing  
11/17/2017Matthew E KorenbergVPSell6,559$142.63$935,510.178,147View SEC Filing  
11/16/2017John L HigginsCEOSell5,269$142.53$750,990.57143,542View SEC Filing  
11/16/2017John W KozarichDirectorSell5,000$141.71$708,550.0035,649View SEC Filing  
9/5/2017John L HigginsCEOSell5,000$130.00$650,000.00144,171View SEC Filing  
8/23/2017Jason AryehDirectorSell2,000$127.99$255,980.0059,625View SEC Filing  
8/9/2017Charles S BerkmanVPSell18,625$126.96$2,364,630.0024,423View SEC Filing  
8/9/2017Matthew W FoehrInsiderSell6,100$127.51$777,811.00101,020View SEC Filing  
8/8/2017John L HigginsCEOSell5,483$125.00$685,375.00144,654View SEC Filing  
6/21/2017John L HigginsCEOSell4,666$120.00$559,920.00143,837View SEC Filing  
6/9/2017John L HigginsCEOSell12,000$114.87$1,378,440.00151,171View SEC Filing  
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.7258,959View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.2098,341View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00139,171View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.8197,599View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.0058,959View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.4958,959View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.4058,959View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00122,664View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.0039,983View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.4040,783View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.0041,783View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.0042,883View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.0043,361View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.003,297View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.0058,337View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.0043,911View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.0044,711View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.0083,062View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.2258,337View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51120,220View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.0449,711View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.003,151View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.0032,536View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.0021,356View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.0063,743View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.8031,243View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.0053,457View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.0044,929View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.0017,667View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.0063,743View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.4226,936View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.2917,928View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00116,581View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.0024,166View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ligand Pharmaceuticals (NASDAQ LGND) News Headlines

Source:
DateHeadline
Ligand Pharmaceuticals (LGND) Presents At Berenberg Conference USA - SlideshowLigand Pharmaceuticals (LGND) Presents At Berenberg Conference USA - Slideshow
seekingalpha.com - May 26 at 8:40 AM
SWTUY or LGND: Which Is the Better Value Stock Right Now?SWTUY or LGND: Which Is the Better Value Stock Right Now?
finance.yahoo.com - May 24 at 5:11 PM
Ligand Pharmaceuticals (LGND) Receives Average Recommendation of "Buy" from AnalystsLigand Pharmaceuticals (LGND) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 20 at 8:14 AM
Ligand Pharma (LGND) Prices Offering of $650 Million of Convertible Senior NotesLigand Pharma (LGND) Prices Offering of $650 Million of Convertible Senior Notes
www.streetinsider.com - May 19 at 8:39 AM
What You Must Know About Ligand Pharmaceuticals Incorporated’s (NASDAQ:LGND) Financial StrengthWhat You Must Know About Ligand Pharmaceuticals Incorporated’s (NASDAQ:LGND) Financial Strength
finance.yahoo.com - May 18 at 5:23 PM
Ligand Prices Offering of $650 Million of Convertible Senior NotesLigand Prices Offering of $650 Million of Convertible Senior Notes
finance.yahoo.com - May 18 at 9:20 AM
Ligand Pharmaceuticals (LGND) Expected to Announce Quarterly Sales of $38.96 MillionLigand Pharmaceuticals (LGND) Expected to Announce Quarterly Sales of $38.96 Million
www.americanbankingnews.com - May 18 at 1:59 AM
Benzingas Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And MoreBenzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More
www.benzinga.com - May 17 at 5:38 PM
Amgens (AMGN) Repatha Gains EU Nod to Include Outcomes DataAmgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
www.nasdaq.com - May 17 at 5:38 PM
BRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior NotesBRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes
www.reuters.com - May 17 at 5:38 PM
Ligand Pharma (LGND) Proposed Offering of $650M of Convertible Senior NotesLigand Pharma (LGND) Proposed Offering of $650M of Convertible Senior Notes
www.streetinsider.com - May 17 at 8:56 AM
Todays Research Reports on Trending Tickers: OPKO Health and Ligand PharmaceuticalsToday's Research Reports on Trending Tickers: OPKO Health and Ligand Pharmaceuticals
finance.yahoo.com - May 17 at 8:56 AM
Ligand Pharmaceuticals (LGND) Expected to Announce Earnings of $0.71 Per ShareLigand Pharmaceuticals (LGND) Expected to Announce Earnings of $0.71 Per Share
www.americanbankingnews.com - May 16 at 9:16 PM
Ligand Pharma readies $650M convertible debt offeringLigand Pharma readies $650M convertible debt offering
seekingalpha.com - May 16 at 5:09 PM
Ligand Announces Proposed Offering of $650 Million of Convertible Senior NotesLigand Announces Proposed Offering of $650 Million of Convertible Senior Notes
finance.yahoo.com - May 16 at 5:09 PM
Ligand Pharmaceuticals (LGND) CEO Sells $2,232,527.85 in StockLigand Pharmaceuticals (LGND) CEO Sells $2,232,527.85 in Stock
www.americanbankingnews.com - May 15 at 7:17 PM
Edited Transcript of LGND earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of LGND earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 12 at 9:08 AM
Ligand Pharmaceuticals (LGND) Insider Sells $1,488,722.03 in StockLigand Pharmaceuticals (LGND) Insider Sells $1,488,722.03 in Stock
www.americanbankingnews.com - May 11 at 7:41 PM
Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares DownGeron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
finance.yahoo.com - May 11 at 5:21 PM
Ligand Pharmaceuticals (LGND) Upgraded to A- by TheStreetLigand Pharmaceuticals (LGND) Upgraded to A- by TheStreet
www.americanbankingnews.com - May 11 at 3:53 PM
Ligand to Participate in Upcoming Investor ConferencesLigand to Participate in Upcoming Investor Conferences
finance.yahoo.com - May 11 at 9:13 AM
Xiaflex & Sterile Injectables Drive Endos (ENDP) Q1 EarningsXiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
www.msn.com - May 10 at 5:24 PM
Ligand (LGND) Beats on Q1 Earnings & Revenues, Keeps ViewLigand (LGND) Beats on Q1 Earnings & Revenues, Keeps View
finance.yahoo.com - May 9 at 5:08 PM
Infinity (INFI) Incurs In-Line Loss in Q1, Maintains ViewInfinity (INFI) Incurs In-Line Loss in Q1, Maintains View
finance.yahoo.com - May 9 at 5:08 PM
HC Wainwright Reaffirms Buy Rating for Ligand Pharmaceuticals (LGND)HC Wainwright Reaffirms Buy Rating for Ligand Pharmaceuticals (LGND)
www.americanbankingnews.com - May 9 at 3:12 PM
Ligand Pharmaceuticals (LGND) CEO John Higgins on Q1 2018 Results - Earnings CallLigand Pharmaceuticals' (LGND) CEO John Higgins on Q1 2018 Results - Earnings Call
seekingalpha.com - May 9 at 8:49 AM
Ligand Pharma (LGND) Tops Q1 EPS by 40cLigand Pharma (LGND) Tops Q1 EPS by 40c
www.streetinsider.com - May 9 at 8:49 AM
Ligand Pharmaceuticals (LGND) Issues Quarterly  Earnings ResultsLigand Pharmaceuticals (LGND) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 7:50 PM
Ligand Pharmaceuticals (LGND) Issues FY18 Earnings GuidanceLigand Pharmaceuticals (LGND) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 6:52 PM
Ligand Pharmaceuticals Inc Q1 adjusted earnings Beat EstimatesLigand Pharmaceuticals Inc Q1 adjusted earnings Beat Estimates
www.nasdaq.com - May 8 at 5:09 PM
Ligand: 1Q Earnings SnapshotLigand: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:09 PM
Agios (AGIO) Q1 Loss Wider than Expected, Revenues MissAgios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
finance.yahoo.com - May 7 at 5:14 PM
Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales MissAlnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
finance.yahoo.com - May 7 at 8:44 AM
AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts ViewAMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View
finance.yahoo.com - May 4 at 5:03 PM
Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1
finance.yahoo.com - May 4 at 5:03 PM
Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEOAchillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO
www.msn.com - May 3 at 5:01 PM
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1
finance.yahoo.com - May 3 at 5:01 PM
What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)
finance.yahoo.com - May 3 at 8:41 AM
Ligand Pharmaceuticals (LGND) Rating Increased to Buy at ValuEngineLigand Pharmaceuticals (LGND) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 3 at 12:39 AM
What Lies Ahead for Ligand (LGND) This Earnings Season?What Lies Ahead for Ligand (LGND) This Earnings Season?
finance.yahoo.com - May 2 at 5:11 PM
Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on TuesdayLigand Pharmaceuticals (LGND) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 4:40 AM
 Brokerages Expect Ligand Pharmaceuticals (LGND) Will Post Quarterly Sales of $32.34 Million Brokerages Expect Ligand Pharmaceuticals (LGND) Will Post Quarterly Sales of $32.34 Million
www.americanbankingnews.com - May 1 at 3:50 AM
Ligand Pharmaceuticals Incorporated (LGND) Sees Hammer Chart Pattern: Time to Buy?Ligand Pharmaceuticals Incorporated (LGND) Sees Hammer Chart Pattern: Time to Buy?
www.zacks.com - April 30 at 8:51 AM
 Analysts Expect Ligand Pharmaceuticals (LGND) Will Announce Earnings of $1.28 Per Share Analysts Expect Ligand Pharmaceuticals (LGND) Will Announce Earnings of $1.28 Per Share
www.americanbankingnews.com - April 29 at 9:16 AM
Vertex (VRTX) Q1 Earnings Beat on Strong CF Products SalesVertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
finance.yahoo.com - April 27 at 4:58 PM
Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales BeatRoche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat
finance.yahoo.com - April 27 at 4:58 PM
Alexions (ALXN) Earnings Beat Estimates in Q1, Guidance UpAlexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
finance.yahoo.com - April 26 at 4:59 PM
Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance UpAlexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
finance.yahoo.com - April 26 at 4:59 PM
Ligand Pharmaceuticals (LGND) Lowered to "Hold" at ValuEngineLigand Pharmaceuticals (LGND) Lowered to "Hold" at ValuEngine
www.americanbankingnews.com - April 26 at 2:04 PM
Ligand Pharmaceuticals (LGND) Given Average Recommendation of "Buy" by BrokeragesLigand Pharmaceuticals (LGND) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 8:50 AM

SEC Filings

Ligand Pharmaceuticals (NASDAQ:LGND) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ligand Pharmaceuticals (NASDAQ:LGND) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ligand Pharmaceuticals (NASDAQ LGND) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.